Kalvista Pharmaceuticals Inc Boston, MA - 02116

Kalvista Pharmaceuticals Inc is categorized under Commercial Biotechnical Research in Boston, MA and active since 2012.

Kalvista Pharmaceuticals Inc was established in 2012, and today employs 1 to 4, earning $50.000 to $99.999 per year. This is a Commercial Biotechnical Research business, which does work in the B2B market, and is classified as a Commercial Biotechnical Research, under code number 541711 by the NAICS.

If you are seeking more information, feel free to contact Thomas Crockett at the company’s single location by writing to 75 Arlington St # 500, Boston, Massachusetts MA 02116 or by phoning (857) 241-3897. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.

Business Name: Kalvista Pharmaceuticals Inc
Contact Person: Thomas Crockett
Address: 75 Arlington St # 500, Boston, Massachusetts 02116
Phone Number: (857) 241-3897
Annual Revenue (USD): $50.000 to $99.999
Founded: 2012
Location Type: Single Location
Employee Number: 1 to 4
Business Type: B2B (Business to Business)
Business Category: Commercial Biotechnical Research
SIC Code: 8731
NAICS Code: 541711
Share This Business:

Kalvista Pharmaceuticals Inc was started in 2012 to provide professional Commercial Biotechnical Research under the SIC code 8731 and NAICS code 541711. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $50.000 to $99.999 per annum.

Feel free to contact Thomas Crockett for inquiries that concern Kalvista Pharmaceuticals Inc by calling the company number (857) 241-3897, as your correspondence is most welcome. Additionally, the physical location of the single location of Kalvista Pharmaceuticals Inc can be found at the coordinates 42.350581,-71.07035 as well as the street address 75 Arlington St # 500 in Boston, Massachusetts 02116.

For its online presence, you may visit Kalvista Pharmaceuticals Inc’s website at and engage with its social media outlets through on Twitter and on Facebook.